Article thumbnail

Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study

By Marcel Schouten, Koenraad F van der Sluijs, Bruce Gerlitz, Brian W Grinnell, Joris JTH Roelofs, Marcel M Levi, Cornelis van 't Veer and Tom van der Poll
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2887187
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2003). Abe T: Renal involvement in children with influenza A virus infection. Pediatr Nephrol
  2. (2004). Abraham E: Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood
  3. (2008). Activated protein C in sepsis: a critical review. Curr Opin Hematol
  4. (1991). Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study. Thorax
  5. (1990). Aycart MD: Community viral pneumonia in the adult population: a prospective multicenter study of 62 cases. The Pneumonia Study Group of the Community of Valencia. Rev Clin Esp
  6. (2009). BW: Distinct functions of activated protein C differentially attenuate acute kidney injury.
  7. (2009). CJ: Biomarkers of thrombosis, fibrinolysis, and inflammation in patients with severe sepsis due to community-acquired pneumonia with and without Streptococcus pneumoniae. Infection
  8. (2009). Cordova-Villalobos JA: Pneumonia and respiratory failure from swine-origin Influenza. A (H1N1) in Mexico.
  9. (2008). Crit Care Med
  10. (2005). CS: Protein C in pneumonia. Thorax
  11. (2005). CT: Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. J Thromb Haemost
  12. (2009). Dating the emergence of pandemic influenza viruses. Proc Natl Acad Sci USA
  13. (2004). der: Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection.
  14. (2005). der: Enhanced viral clearance in interleukin-18 gene-deficient mice after pulmonary infection with influenza A virus. Immunology
  15. (2008). der: Inflammation, endothelium, and coagulation in sepsis.
  16. (2004). der: Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax
  17. (2006). der: Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med
  18. (2007). der: Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation. Eur Respir J
  19. (2003). der: Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood
  20. (2009). der: Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology
  21. (2002). der: Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia.
  22. (2005). Dhainaut JF: Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med
  23. (2004). DR: Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med
  24. (2002). DS: Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther
  25. (2005). E: Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med
  26. (2006). Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Circ Res
  27. (2001). Efficacy and safety of recombinant human activated protein C for severe sepsis.
  28. (2007). Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med
  29. (2003). Engineering the proteolytic specificity of activated protein C improves its pharmacological properties. Proc Natl Acad Sci USA
  30. (2000). Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost
  31. (2005). Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respir Med
  32. (1984). Evidence for the occurrence of a fastacting inhibitor for tissue-type plasminogen-activator in humanplasma. Thromb Haemost
  33. (1982). FE: A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost
  34. (2009). JH: Hyper-antithrombotic, non-cytoprotective Glu149Ala-activated protein C mutant. Blood
  35. (2007). JH: The cytoprotective protein C pathway. Blood
  36. (1987). KE: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.
  37. (2004). Lowry SF: Effects of drotrecogin alfa (activated) in human endotoxemia. Shock
  38. (2008). MJ: Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med
  39. (2007). MJ: Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med
  40. (2006). Mortality due to influenza in the United States--an annualized regression approach using multiple-cause mortality data.
  41. (1985). MS: Whole-blood clot lysis - In vitro modulation by activated protein C. Thromb Res
  42. (2000). OP: Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappa B (NF-kappa B) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line.
  43. (1996). PB: The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood
  44. (1993). Rylatt DB: Automated-determination of cross-linked fibrin derivatives in plasma. Blood Coagul Fibrinolysis
  45. (2004). Taguchi O: Protective role of activated protein C in lung and airway remodeling. Crit Care Med
  46. (1996). Takatsuki K: Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood
  47. (1997). Takatsuki K: Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production.
  48. (2004). Vallance P: Risk of myocardial infarction and stroke after acute infection or vaccination.
  49. (2000). W: Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia - Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med